NIH R01 · 2025
Glioblastoma (GBM) is highly resistant and uniformly fatal despite current therapeutic efforts. Intra-tumoral malignant reprogramming evolution of GBM stem cells (GSCs) towards a highly resistant and invasive mesenchymal-like (MES) phenotype has emerged as a leading hypothesis for GBM lethality. Unfortunately, there are currently no therapeutic strategies that address malignant reprogramming in GBM. Our long-term goal is to develop such therapies. The current proposal is significant in that it presents a potential therapeutic approach that targets malignant reprogramming of GSCs to improve GBM survival. It builds upon our validation of the mechanistic underpinnings of BIRC3/STAT3 signaling…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.